amvuttra(VUTRISIRAN)Medication DetailsAlnylam Pharmaceuticals, Inc.Usage: AMVUTTRA is indicated for treating the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.Medication Details
givlaari(givosiran sodium)Medication DetailsAlnylam Pharmaceuticals, Inc.Usage: GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).Medication DetailsDrug Interactions
onpattro(patisiran)Medication DetailsAlnylam Pharmaceuticals, Inc.Usage: ONPATTRO is indicated for treating the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.Medication Details
oxlumo(lumasiran)Medication DetailsAlnylam Pharmaceuticals, Inc.Usage: OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to reduce urinary and plasma oxalate levels in both pediatric and adult patients.Medication Details